These findings fall within the range reported in global studies; the prevalence of HER2 mutations in NSCLC reported in global studies ranged from 0.3% to 9.1%, whereas the prevalence of HER2 amplification ranged from 0.2% to 19%. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.